Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway

Cao, Wanshuang; Li, Yuan; Sun, Hongzan; Yang, Chenying; Zhu, Jianyun; Xie, Chunfeng; Li, Xiaoting; Wu, Jieshu; Geng, Shanshan; Wang, Lu; Sun, Liangfei; Geng, Guoxia; Han, Hongmei; Zhong, Caiyun

doi:10.3389/fcell.2021.679806

Cited by 14 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Ge et al (2019) found that sulforaphane suppresses the stemness of GC stem cells by inhibiting the Hedgehog pathway. It is reported that Apatinib suppresses GC stem cells properties via inhibiting the Hedgehog pathway ( Cao et al, 2021 ). Low levels of DIM promoted GC progression by activating the Wnt4 pathway to enhance GC cell stemness ( Zhu et al, 2016 ).…”

Section: Effects Of Phytochemicals On the Occurrence And Development ...mentioning

confidence: 99%

Anticancer applications of phytochemicals in gastric cancer: Effects and molecular mechanism

Liang

Zhang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Gastric cancer (GC) is the fourth most common malignant cancer and is a life-threatening disease worldwide. Phytochemicals have been shown to be a rational, safe, non-toxic, and very promising approach to the prevention and treatment of cancer. It has been found that phytochemicals have protective effects against GC through inhibiting cell proliferation, inducing apoptosis and autophagy, suppressing cell invasion and migration, anti-angiogenesis, inhibit Helicobacter pylori infection, regulating the microenvironment. In recent years, the role of phytochemicals in the occurrence, development, drug resistance and prognosis of GC has attracted more and more attention. In order to better understand the relationship between phytochemicals and gastric cancer, we briefly summarize the roles and functions of phytochemicals in GC tumorigenesis, development and prognosis. This review will probably help guide the public to prevent the occurrence and development of GC through phytochemicals, and develop functional foods or drugs for the prevention and treatment of gastric cancer.

show abstract

Section: Effects Of Phytochemicals On the Occurrence And Development ...mentioning

confidence: 99%

Anticancer applications of phytochemicals in gastric cancer: Effects and molecular mechanism

Liang

Zhang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…[17][18][19][20] Preclinical studies have shown that apatinib exerts antitumor effects in gastric cancer through a variety of mechanisms. [21][22][23] A previous study that enrolled 273 patients with gastric cancer who progressed after chemotherapy, demonstrated that apatinib treatment significantly improved median PFS and DCR compared with the placebo group. 24 Apatinib has been approved as a third line treatment option for advanced or metastatic gastric cancer or GEJ in China.…”

Section: Discussionmentioning

confidence: 99%

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

Nie

Chen

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objectives: This study was carried out to assess the efficacy and drug toxicity of anti-angiogenic tyrosine kinase inhibitor (TKI) plus chemotherapy as second-line or above therapeutic regime in advanced or metastatic gastric cancer patients. Methods: From November 2017 to April 2020, advanced or metastatic gastric cancer patients who have failed from prior treatment and received apatinib combined with irinotecan or irinotecan treatment were analyzed. The primary observed indicator was progression-free survival (PFS). Objective: response rate (ORR), disease control rate (DCR), overall survival (OS), and drug toxicity were also evaluated. Results: 26 patients received apatinib combined with irinotecan and 29 patients received irinotecan. The ORR in the combination therapy and monotherapy population was 26.9% and 17.2%, respectively. The DCR in the apatinib combined with irinotecan group was higher than in irinotecan monotherapy population (80.8% vs 55.2%, P = .043). Median PFS was 4.2 months in the combination group and 3.3 months in the monotherapy group ( P = .020). Median OS was 8.0 months in the combination group and 5.9 months in the monotherapy group ( P = .048). Except for ECOG PS 2, PFS and OS were generally consistent across subgroups by sex, age, number of metastatic sites and primary tumor site. The incidence of Grade 3–4 adverse events in combination and monotherapy group was 23.1% and 20.7%, respectively. In apatinib combined with irinotecan group, adverse events that were attributed to apatinib were secondary hypertension (in seven patients, 26.9%), hand-foot syndrome (5,19.2%), and proteinuria (5, 19.2%). Univariate analysis demonstrated that secondary hypertension was considered to be a favorable factor ( P = .040) for longer OS in combination therapy group. Conclusions: Compared with chemotherapy alone, anti-angiogenic TKI plus chemotherapy showed better PFS, OS and DCR in advanced or metastatic gastric cancer as second-line or above therapy, with a tolerable and manageable safety profile.

show abstract

“…Wanshuang Cao et al found that Apatinib can inhibit the stemness of GC cells through the Hedgehog signaling pathway. The specific mechanism is that Apatinib acts by inhibiting the key protein SMO in the Hedgehog signaling pathway [ 147 ]. P H Nguyen et al found that all-trans retinoic acid targets GCSCs and inhibits patient-derived gastric carcinoma tumor growth.…”

Section: Drugs For Gc Treatment By Targeting Its Stemnessmentioning

confidence: 99%

Targeting Gastric Cancer Stem Cells to Enhance Treatment Response

Rao

Zhang

Luo

et al. 2022

Cells

View full text Add to dashboard Cite

Gastric cancer (GC) was the fourth deadliest cancer in the world in 2020, and about 770,000 people died from GC that year. The death of patients with GC is mainly caused by the metastasis, recurrence, and chemotherapy resistance of GC cells. The cancer stem cell theory defines cancer stem cells (CSCs) as a key factor in the metastasis, recurrence, and chemotherapy resistance of cancer. It considers targeting gastric cancer stem cells (GCSCs) to be an effective method for the treatment of GC. For GCSCs, genes or noncoding RNAs are important regulatory factors. Many experimental studies have found that some drugs can target the stemness of gastric cancer by regulating these genes or noncoding RNAs, which may bring new directions for the clinical treatment of gastric cancer. Therefore, this review mainly discusses related genes or noncoding RNAs in GCSCs and drugs that target its stemness, thereby providing some information for the treatment of GC.

show abstract

Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway

Cited by 14 publications

References 44 publications

Anticancer applications of phytochemicals in gastric cancer: Effects and molecular mechanism

Anticancer applications of phytochemicals in gastric cancer: Effects and molecular mechanism

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

Targeting Gastric Cancer Stem Cells to Enhance Treatment Response

Contact Info

Product

Resources

About